Borer, J., Armstrong, P., & Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee, . (2003). Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. Circulation, 107(23), e9052. https://doi.org/10.1161/01.CIR.0000082691.46188.C8

Borer, Jeffrey, Paul Armstrong, and Paul Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. “Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.” Circulation 107, no. 23 (June 17, 2003): e9052. https://doi.org/10.1161/01.CIR.0000082691.46188.C8.

Borer J, Armstrong P, Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. Circulation. 2003 Jun 17;107(23):e9052.

Borer, Jeffrey, et al. “Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.” Circulation, vol. 107, no. 23, June 2003, p. e9052. Pubmed, doi:10.1161/01.CIR.0000082691.46188.C8.

Borer J, Armstrong P, Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. Circulation. 2003 Jun 17;107(23):e9052.